Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleCELLULAR AND MOLECULAR

Simultaneous α2B- and β2-Adrenoceptor Activation Sensitizes the α2B-Adrenoceptor for Agonist-Induced Down-Regulation

Aarti N. Desai, Kelly M. Standifer and Douglas C. Eikenburg
Journal of Pharmacology and Experimental Therapeutics November 2004, 311 (2) 794-802; DOI: https://doi.org/10.1124/jpet.104.069674
Aarti N. Desai
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kelly M. Standifer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Douglas C. Eikenburg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

We recently reported that α2A-adrenoceptor (AR) desensitization and down-regulation occurs after 24-h treatment with epinephrine (EPI) (0.3 μM) in BE(2)-C cells that express both α2- and β2-ARs. The same concentration of norepinephrine (NE) has no effect. The effect of EPI is prevented by β2-AR blockade and is associated with an increase in G protein-coupled receptor kinase 3 (GRK3) expression. Because differences in agonist-induced down-regulation of the α2A-versus α2B-ARs have been reported, the present study examines the effects of simultaneous activation of α2B- and β2-ARs on α2B-AR number and signaling. We studied NG108 cells that naturally express α2B-ARs, and BN17 cells, NG108 cells transfected to express the human β2-AR. In NG108 cells, α2B-AR desensitization and down-regulation require treatment with 20 μM EPI or NE; GRK expression was not changed. In BN17 cells expressing β2-ARs, the threshold EPI concentration for α2B-AR desensitization and down-regulation was reduced to 0.3 μM; 10 μM NE was required for the same effect. Furthermore, 24-h EPI or NE treatments that produced desensitization also resulted in a selective 2-fold up-regulation of GRK3; GRK2 was unchanged. The β-AR antagonist alprenolol (1 μM) and GRK3 antisense (but not sense) DNA blocked 0.3 μM EPI- and 10 μM NE-induced desensitization and down-regulation of the α2B-AR as well as GRK3 up-regulation. In conclusion, simultaneous activation of α2B- and β2-ARs results in a 67-fold decrease in the threshold concentration of EPI required for α2B-AR down-regulation. This lower threshold for down-regulation is associated with α2B- and β2-AR dependent up-regulation of GRK3 expression.

Footnotes

  • The research presented in this publication was supported in part by a grant to D.C.E. from the American Heart Association, Texas Affiliate, and a grant to K.M.S. from the Texas Higher Education Coordinating Board Advanced Research Program (00 36 52-011402001).

  • doi:10.1124/jpet.104.069674.

  • ABBREVIATIONS: GPCR, G protein-coupled receptor; EPI, epinephrine; NE, norepinephrine; PGE1, prostaglandin E1; ODN, oligodeoxynucleotide; AR, adrenoceptor; ISO, isoproterenol; PBS, phosphate-buffered saline; TBS-T, Tris-buffered saline/Tween 20; Alp, alprenolol; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; [3H]RX821002, (1,4-[6,7)(n)-3H]benzodioxan-2-methoxy-2-yl)-2-imidazoline hydrochloride.

    • Received April 15, 2004.
    • Accepted June 10, 2004.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 311 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 311, Issue 2
1 Nov 2004
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Simultaneous α2B- and β2-Adrenoceptor Activation Sensitizes the α2B-Adrenoceptor for Agonist-Induced Down-Regulation
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleCELLULAR AND MOLECULAR

Simultaneous α2B- and β2-Adrenoceptor Activation Sensitizes the α2B-Adrenoceptor for Agonist-Induced Down-Regulation

Aarti N. Desai, Kelly M. Standifer and Douglas C. Eikenburg
Journal of Pharmacology and Experimental Therapeutics November 1, 2004, 311 (2) 794-802; DOI: https://doi.org/10.1124/jpet.104.069674

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleCELLULAR AND MOLECULAR

Simultaneous α2B- and β2-Adrenoceptor Activation Sensitizes the α2B-Adrenoceptor for Agonist-Induced Down-Regulation

Aarti N. Desai, Kelly M. Standifer and Douglas C. Eikenburg
Journal of Pharmacology and Experimental Therapeutics November 1, 2004, 311 (2) 794-802; DOI: https://doi.org/10.1124/jpet.104.069674
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • CsA downregulates Selenop expression via a STAT3-FoxO1 axis
  • Anisodamine Ameliorates Acute Lung Injury
  • ACE2 Inhibits LPS-Caused Lung Fibrosis
Show more Cellular and Molecular

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics